Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

v3.20.1
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)
Total
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Stockholders Deficit TransBiotec Inc [Member]
Noncontrolling Interest [Member]
Balance, shares at Dec. 31, 2017 109,409,930 1,388,575
Balance, amount at Dec. 31, 2017 $ (2,964,137) $ 1,096 $ 14 $ 14,785,051 $ (17,703,171) $ (2,917,010) $ (47,127)
Common stock issued for services, shares   6,000,000          
Common stock issued for services, amount 25,800 $ 61   25,739   25,800  
Common stock issued for compensation, shares   800,000          
Common stock issued for compensation, amount 8,000 $ 9   7,991   8,000  
Common stock issued due to options exercise, shares   450,000          
Common stock issued due to options exercise, amount 4,500 $ 5   4,495 4,500  
Common stock issued to settle non-related party debt, shares   91,148          
Common stock issued to settle non-related party debt, amount 428 $ 1   427   428  
Paid-in capital - beneficial conversion feature 6,000   6,000   6,000  
Paid-in capital - relative fair value of stock warrants granted 29,701   29,701   29,701  
Paid-in capital - gain on related party debt conversion 28,400   28,400   28,400  
Net Income (Loss) $ (562,123) $ (558,965) $ (558,965) $ (3,158)
Paid-in capital - value of convertible preferred stock removed upon conversion to common stock, amount            
Balance, shares at Dec. 31, 2018 116,751,078 1,388,575
Balance, amount at Dec. 31, 2018 $ (3,423,431) $ 1,172 $ 14 $ 14,887,804 $ (18,262,136) $ (3,373,146) $ (50,285)
Common stock issued for compensation, shares   14,000,000          
Common stock issued for compensation, amount 59,500 $ 140   59,360   59,500  
Paid-in capital - beneficial conversion feature 5,589   5,589   5,589  
Paid-in capital - relative fair value of stock warrants granted 160,544   160,544   160,544  
Net Income (Loss) (1,252,157) $ (1,249,032) (1,249,032) $ (3,125)
Paid-in capital - value of convertible preferred stock removed upon conversion to common stock, amount (1,388,575) $ (14) (1,388,561)   (1,388,575)  
Paid-in capital - value of convertible preferred stock removed upon conversion to common stock, shares   (1,388,575)        
Common stock issued for cash, shares   35,454,547          
Common stock issued for cash, amount 39,000 $ 350   38,650   39,000  
Common stock issued due to stock warrants exercise, shares   34,535,165          
Common stock issued due to stock warrants exercise, amount 146,774 $ 345   146,429   146,774  
Common stock issued upon conversion of convertible preferred stock to common stock, shares   13,885,750          
Common stock issued upon conversion of convertible preferred stock to common stock, amount 59,015 $ 139   58,876   59,015  
Paid-in capital - fair value of related party stock options vested 71,655   71,655   71,655  
Paid-in capital - fair value of non-related party stock options granted 23,912   23,912   23,912  
Paid-in capital - gain on related party executive compensation conversion 535,500   535,500   535,500  
Paid-in capital - gain on related party debt conversion 39,992   39,992   39,992  
Paid-in capital - gain on related party preferred stock conversion $ 1,329,561   $ 1,329,561   $ 1,329,561  
Balance, shares at Dec. 31, 2019 214,626,540
Balance, amount at Dec. 31, 2019 $ (3,593,121) $ 2,146 $ 15,969,311 $ (19,511,168) $ (3,539,711) $ (53,410)